Table 2.
Extracellular vesicle (EV) concentration and percentage [%] of Annexin V+ EV in survivors and non-survivors of VA-ECMO therapy.
| Parameter | Survivor | Non-survivor | p-value |
|---|---|---|---|
| Total Annexin V+ EV/ml | 16,451 ± 2,506 | 34,447 ± 7,449 | 0.01 |
| CD61+ EV/ml | 6,079 ± 1,081 | 15,912 ± 5,524 | 0.03 |
| Caveolin-3+ EV/ml | 230.9 ± 67.43 | 559.7 ± 293.1 | 0.87 |
| CD45+ EV/ml | 345.4 ± 217.8 | 3,380 ± 2,044 | 0.05 |
| CD62E+ EV/ml | 871.8 ± 789.3 | 105.0 ± 39.2 | 0.53 |
| CD235a+ EV/ml | 2,750 ± 822.9 | 5,922 ± 2,135 | 0.11 |
| CD61+ EV [%] | 38.4 ± 5.0 | 43.1 ± 16.7 | 0.73 |
| Caveolin-3+ EV [%] | 1.7 ± 0.4 | 1.4 ± 0.5 | 0.70 |
| CD45+ EV [%] | 2.1 ± 0.8 | 7.9 ± 4.9 | 0.12 |
| CD62E+ EV [%] | 4.1 ± 3.6 | 0.2 ± 0.1 | 0.45 |
| CD235a+ EV [%] | 18.0 ± 4.2 | 13.9 ± 3.9 | 0.54 |
CD61+ (platelet) EV, caveolin-3+ (cardiomyocyte) EV, CD45+ (leukocyte) EV, CD62E+ (endothelial) EV, CD235a+ (erythrocyte) EV. Data are presented as mean±SEM. p-values were calculated by an unpaired Student's t-test. Significant p-values are indicated in bold.